Yanhan Dong

Title: Innovations in Lung Adenocarcinoma Treatment by Yanhan Dong

Introduction

Yanhan Dong is a prominent inventor based in Qingdao, China, known for his significant contributions to biomedical technology. His innovative work focuses on developing targeted therapeutic drugs aimed at inhibiting the proliferation of lung adenocarcinoma cells.

Latest Patents

Yanhan Dong holds a patent for the use of PIWI-interacting RNA piR-hsa-211106. This invention is pivotal in the field of cancer treatment, specifically targeting lung adenocarcinoma. The mechanism involves constructing the PIWI-interacting RNA piR-hsa-211106 into an agonist or a transformant, which subsequently inhibits the tricarboxylic acid cycle process. This is achieved by down-regulating the expression of pyruvate carboxylase, leading to reduced energy metabolism and promoting apoptosis in lung adenocarcinoma cells. The direct action of this RNA on target sites ensures minimal toxic effects and avoids off-target phenomena. Extensive analyses and both in-vivo and in-vitro experiments have demonstrated the high credibility and remarkable treatment effects of this innovation, paving a new research direction for anti-tumor therapy.

Career Highlights

Throughout his career, Yanhan Dong has focused on advancing cancer treatment methodologies. His dedication to research and innovation has led to significant breakthroughs in understanding and combating lung adenocarcinoma.

Collaborations

Yanhan Dong has collaborated with notable colleagues, including Wenhua Xu and Yongmei Liu, to enhance the research and development of his patented technologies.

Conclusion

Yanhan Dong's work exemplifies the potential of innovative biomedical technologies in the fight against cancer. His contributions, particularly through the PIWI-interacting RNA piR-hsa-211106, represent a significant advancement in targeted cancer therapies.